Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis

Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.

Figure 2 Risk of bias assessment of included studies using risk of bias in non-randomized studies-of interventions tool.

Figure 3 Forest plots comparing dabigatran with warfarin regarding hazard ratios of ischemic stroke, all-cause mortality, major bleeding, intracranial hemorrhage, and gastrointestinal bleeding. HR: Hazard ratio; CI: Confidence interval.

Figure 4 Forest plots comparing rivaroxaban with warfarin regarding hazard ratio of ischemic stroke, all-cause mortality, major bleeding, intracranial hemorrhage, and gastrointestinal bleeding. HR: Hazard ratio; CI: Confidence interval.

Figure 5 Forest plots comparing apixaban with warfarin regarding hazard ratio of ischemic stroke, all-cause mortality, major bleeding, intracranial hemorrhage, gastrointestinal bleeding. HR: Hazard ratio; CI: Confidence interval.